GuidelinesEAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease
Introduction
The most recent summary of the European Association of Urology (EAU) guidelines on prostate cancer (PCa) was published in 2008 [1]. The long version of these guidelines has been continuously updated because many important changes affecting the clinical management of PCa have occurred. This paper summarises the 2010 update of the EAU guidelines on PCa. To facilitate evaluating the quality of the information provided, level of evidence (LE) and grade of recommendation (GR) have been inserted according to the general principles of evidence-based medicine [2].
Section snippets
Epidemiology
In Europe, PCa is the most common solid neoplasm, with an incidence rate of 214 cases per 1000 men, outnumbering lung and colorectal cancer [3]. PCa affects elderly men more often and therefore is a bigger health concern in developed countries. Thus about 15% of male cancers are PCa in developed countries compared with 4% of male cancers in developing countries [4]. There are large regional differences in incidence rates of PCa with a range from 68.8 in Malta to 182 in Belgium [4].
Risk factors
The factors that determine the risk of developing clinical PCa are not well known, although three well-established risk factors have been identified: increasing age, ethnicity, and heredity.
If one first-line relative has the disease, the risk is at least doubled. If two or more first-line relatives are affected, the risk increases 5- to 11-fold [5]. About 9% of individuals with PCa have true hereditary PCa, defined as three or more relatives affected or at least two who have developed
Classifications
The Union Internationale Contre le Cancer 2009 TNM classification is used throughout the guidelines [6]. The Gleason score is recommended for grading PCa. According to current international convention, the (modified) Gleason score of cancers detected in a prostate biopsy consists of the Gleason grade of the dominant (most extensive) carcinoma component plus the highest grade, regardless of its extent (no 5% rule) [7]. In radical prostatectomy (RP) specimens, both the primary and the secondary
Prostate cancer screening
There is currently no evidence for introducing widespread population-based screening programmes for early PCa detection in all men [8] (LE: 2). To evaluate the efficacy of PCa screening, two large randomised trials have been published: the Prostate, Lung, Colorectal, and Ovary (PLCO) trial in the United States and the European Randomised Study of Screening for Prostate Cancer (ERSPC) in Europe [9], [10] (LE: 1b).
The PLCO cancer screening trial randomly assigned 76 693 men to receive either
Diagnosis and staging of prostate cancer
The main diagnostic tools to diagnose PCa include DRE, serum concentration of PSA, and transrectal ultrasound (TRUS)–guided biopsies. In about 18% of all patients, PCa is detected by a suspect DRE alone, irrespective of the PSA level [14] (LE: 2a). A suspect DRE in patients with a PSA level of up to 2 ng/ml has a positive predictive value of 5–30% [15] (LE: 2a).
A threshold level of PSA that indicates the highest risk of PCa needs to be defined (Table 1). When analysing PSA serum levels, it has
Primary local treatment of prostate cancer
Therapeutic management of PCa, even in clinically localised disease, has become more and more complex because of the various stage-specific therapeutic options available. It is advisable (1) to counsel patients with low-risk PCa (PSA < 10 ng/ml and biopsy Gleason score 6 and cT1c–cT2a) or intermediate-risk PCa (PSA 10.1–20 ng/ml or biopsy Gleason score 7 or cT2b–c) in an interdisciplinary setting with an urologist and a radiation oncologist, (2) to discuss neoadjuvant and adjuvant treatment
Follow-up of prostate cancer patients
Patients diagnosed with PCa who underwent local treatment with curative intent are usually followed for at least 10 yr or until advanced age makes follow-up superfluous (Table 5). Determination of serum PSA together with a disease-specific history can be supplemented by DRE if locally recurrent disease is suspected.
Alternative local treatment options of prostate cancer
In addition to RP, EBRT, and/or brachytherapy, cryosurgical ablation of the prostate (CSAP) and high-intensity focussed ultrasound (HIFU) have emerged as alternative therapeutic options in patients with clinically localised PCa who are not suitable for RP [84], [85]. However, at the time of writing, data from HIFU were not extensive enough to be considered in treatment recommendations. Applying the Grading of Recommendations Assessment, Development and Evaluation approach, the available
Summary
The present text represents a summary, and for more detailed information and a full list of references, we refer you to the full-text version. These EAU guidelines (ISBN 978-90-79754-70-0) are available at the EAU Web site (www.uroweb.org).
References (86)
- et al.
EAU guidelines on prostate cancer
Eur Urol
(2008) - et al.
Estimates of cancer incidence and mortality in Europe 2008
Eur J Cancer
(2010) Hereditary prostate cancer: clinical aspects
J Urol
(2002)- et al.
Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging
J Urol
(1974) - et al.
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit
Eur J Cancer
(2010) - et al.
Prostate specific antigen testing among the elderly; when to stop?
J Urol
(2008) - et al.
Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less
J Urol
(1999) - et al.
Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy
Urology
(2008) - et al.
Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review
J Urol
(2006) - et al.
Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma
J Urol
(2009)
Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up
Eur Urol
11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms
Eur Urol
Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis
J Urol
When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool
Eur Urol
Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics
J Urol
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0–2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)
Eur Urol
Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods
J Urol
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen
Urology
A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer
Eur Urol
An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer
Eur Urol
Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer
Urology
A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma
Cancer Treat Rev
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy
Lancet Oncol
Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911)
Lancet
Update of SWOG 8794: adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival
Int J Radiat Oncol Biol Phys
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial
J Urol
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995
Int J Radiat Oncol Biol Phys
Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
Lancet
ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer
Radiother Oncol
Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer
J Urol
Ultrahigh dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes
Int J Radiat Oncol Biol Phys
Best practice statement on cryosurgery for the treatment of localized prostate cancer
J Urol
Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer
Eur Urol
Cancer statistics, 2008
CA Cancer J Clin
Screening for prostate cancer: a Cochrane systematic review
Cancer Causes Control
Mortality results from a randomized prostate-cancer screening trial
N Engl J Med
Screening and prostate-cancer mortality in a randomized European study
N Engl J Med
Problems, objective, and substance of early detection of prostate cancer [in German]
Urologe A
What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels?
Nat Clin Pract Urol
Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?
Clin Chem Lab Med
Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter
N Engl J Med
Cited by (1272)
Survival After Cryotherapy Versus Radiotherapy in Low and Intermediate Risk Localized Prostate Cancer
2023, Clinical Genitourinary CancerTo see or not to see: Evaluation of magnetic resonance imaging sequences for use in MR Linac-based radiotherapy treatment
2022, Journal of Medical Imaging and Radiation SciencesUnlocking the potential of oncology biomarkers: advancements in clinical theranostics
2024, Drug Metabolism and Personalized Therapy